Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NXLWWoQzTnWwY4Tpc44hSXO|YYm= M2q5SlAvPcLizszN M{\NW|I1KGh? NVTWZXREf2G2ZYK= M2LFS41w\HWuYYTld{B1cGViZ3Xu[UBmgHC{ZYPzbY9vKG:oIF3BS2UuSSCvZX3i[ZJ{ M3zUXlI2OTJ|MEiy
Eca109 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSwMlUwOi53L{Wg{txO MkPtNlQwPDhxN{KgbC=> NF;nT3d4[XSnch?= NED3e5JqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MY[yOVEzOzB6Mh?=
Eca109 NFrBNo9HfW6ldHnvckBCe3OjeR?= M2q1bVAvPcLizszN MW[2M|EzNzJ2IHi= M133Z5difGW{ M1\HdIlvcGmkaYTzJINmdGxibXnndoF1cW:wwrC= MX:yOVEzOzB6Mh?=
Eca109 MVjGeY5kfGmxbjDBd5NigQ>? NFXT[WQxNjYEoN88US=> NEHCUmgzPCCq MnvJe4F1\XJ? MYTpcohq[mm2czDj[YxtKGmwdnHzbY9v NUjyUmpVOjVzMkOwPFI>
Eca109 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\xcpZkOC53wrFOwG0> M{G4VlI1KGh? NHLRV4x4[XSnch?= NXrTTm9jcW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>? NVTo[FJDOjVzMkOwPFI>
Eca109 NV3qdmhuTnWwY4Tpc44hSXO|YYm= NWPTZnJnOC53L{Gg{txO M2n5TFI1KGh? MUT3ZZRmeg>? NX3JT3ND\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= MlXRNlUyOjNyOEK=
SW1116  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXOcIFOOC53L{GvNk82KM7:TR?= NYfWTY5TPDhiaB?= MoS2SG1UVw>? MXflcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u MkDuNlQ5PzR{OE[=
LOVO NXjC[IY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\qRYgxNjVxMT:yM|Uh|ryP MVy0PEBp MVHEUXNQ NYTxO5BT\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? MUGyOFg4PDJ6Nh?=
SW1116  NVq3O4x2TnWwY4Tpc44hSXO|YYm= M1LxelExKM7:TR?= NFmxVYY1QCCq NEnsfXVFVVOR M1LXfYlv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? MlTqNlQ5PzR{OE[=
LOVO NVu4fFhtTnWwY4Tpc44hSXO|YYm= MlvkNVAh|ryP M1nBc|Q5KGh? NVG4eVh[TE2VTx?= NH3MeWNqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? MUSyOFg4PDJ6Nh?=
SW1116  M4XJcGFxd3C2b4Ppd{BCe3OjeR?= M3\2fFExKM7:TR?= NFmyc5g1QCCq NHzGU5BFVVOR Mnrw[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MWKyOFg4PDJ6Nh?=
LOVO NY[2e5FmSXCxcITvd4l{KEG|c3H5 MlHKNVAh|ryP MUW0PEBp NYnFbmlJTE2VTx?= MVnlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NGO2WHczPDh5NEK4Oi=>
RPMI-8226 M3jkNWFxd3C2b4Ppd{BCe3OjeR?= NHvYWmEyNzJizszN MmL4OFgwPzJxOU[gbC=> MUTEUXNQ M{X1Z4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXSyOFg{OzFyOB?=
OPM-2  M2PXOWFxd3C2b4Ppd{BCe3OjeR?= M2GxR|EwOiEQvF2= MofzO|IwQTZxMUKwJIg> MnTjSG1UVw>? M{\TSYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MVyyOFg{OzFyOB?=
JJN3  NUeyWmFzSXCxcITvd4l{KEG|c3H5 NXnNToJIOC53L{Gg{txO M12welI1NzR6IHi= M1nkXmROW09? M{Hib4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NEXUWJkzPDh|M{GwPC=>
NCI-H929  NWq3XXR2SXCxcITvd4l{KEG|c3H5 NYjKcYxOOS9{IN88US=> M3zyZ|czNzl4L{GyNEBp NXvyfGExTE2VTx?= MofmbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MWqyOFg{OzFyOB?=
RPMI-8226 M2DFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvYd2EyNzJizszN M{LoNlI1NzR6L{eyJIg> M17neGROW09? NXvJflRr[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= M3;nclI1QDN|MUC4
OPM-2  NGD2eohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKxM|Ih|ryP MlWxNlQwPDhxN{KgbC=> NEK1WIJFVVOR M{LOc4Fn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NYXlNHp5OjR6M{OxNFg>
JJN3  M3ywTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCwMlUwOSEQvF2= MV[yOE81QC95MjDo NVHwVHBDTE2VTx?= NWW1Ooo4[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= M1KxUVI1QDN|MUC4
NCI-H929  NFLWPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULvdoM{OS9{IN88US=> NEfGWpozPC92OD:3NkBp MYfEUXNQ MmXuZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? MmTsNlQ5OzNzMEi=
HeLa NYLvc|gzU2mwYYPlJGF{e2G7 NVywXG5OU2l;MUCwNQKBmzVyMECg{txOKG[xcjDoSW5VOQ>? NYCybXVrOjR5OECwPVg>
HeLa NX3LSW1wU2mwYYPlJGF{e2G7 M4rYUGtqRTVwNjFCtUAxNjVizszNJIZweiCqRV7UNi=> NVfpW3poOjR5OECwPVg>
HeLa M{DTSGtqdmG|ZTDBd5NigQ>? NYjpRY55U2l;MkGuOkDDuSB|LkCg{txOKG[xcjDoR25VOQ>? M4jFN|I1PzhyMEm4
HeLa MUnLbY5ie2ViQYPzZZk> Mny1T4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> NWGzb3FuOjR5OECwPVg>
NB4 NFLjXJJHfW6ldHnvckBCe3OjeR?= M1TBVlIvPS93L{euOU8yOCEQvF2= MXiyOEBp NFe4VmRFVVOR MYPpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh NYPpS2dLOjR2OES4O|A>
CD4+ CD25− T  Ml\xSpVv[3Srb36gRZN{[Xl? MmLMNU82KM7:TR?= M1LQfZJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? NV\oUVhIOjR2N{[zOlA>
BV-173 NYTWZWxKSXCxcITvd4l{KEG|c3H5 Moj4NE4zPS9yLkWvNE44PS9zIN88US=> NGnLd2k1QC95Mj:5OkBp M3PuNOKhWEKV NVHoNFl3cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M2fHNFI1PDJ|NkGz
ML-1 MVXBdI9xfG:|aYOgRZN{[Xl? NXnDV|IzOC5{NT:wMlUwOC55NT:xJO69VQ>? M1TyNFQ5Nzd{L{m2JIg> M2PWceKhWEKV NIPJWolqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MXuyOFQzOzZzMx?=
HL-60 M1rabmFxd3C2b4Ppd{BCe3OjeR?= MXKwMlI2NzBwNT:wMlc2NzFizszN M3;FV|Q5Nzd{L{m2JIg> NYPBfYZ6yqCSQmO= M2PWTIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NYKyVItxOjR2MkO2NVM>
KG-1a NE\tc|NCeG:ydH;zbZMhSXO|YYm= NHLm[W0xNjJ3L{CuOU8xNjd3L{Gg{txO MkDLOFgwPzJxOU[gbC=> MYhCpHBDWw>? M{nGTYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NHL4XmszPDR{M{[xNy=>
BV-173 M1S4UGZ2dmO2aX;uJGF{e2G7 M1TDOVI2OC93MEDuUS=> NHHOT3g1QCCq NXnVblFKyqCSQmO= MXjpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NWnQcXJ2OjR2MkO2NVM>
CEM MoXlSpVv[3Srb36gRZN{[Xl? MVSyOVAwPTBybl2= MojYOFghcA>? MVpCpHBDWw>? MXfpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NFnsUWEzPDR{M{[xNy=>
HL-60 NInU[YtHfW6ldHnvckBCe3OjeR?= NYn2Rlh3OjVyL{WwNI5O M3nYNVQ5KGh? NILTfHbDqFCEUx?= NFrGUWxqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= M37wRlI1PDJ|NkGz
ML-1 NWnR[HI5TnWwY4Tpc44hSXO|YYm= NEC1c4gzPTBxNUCwcm0> M{joRlQ5KGh? MmXmxsBRSlN? NIHSWmJqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= Mn61NlQ1OjN4MUO=
DLD-1 M{XVd2Z2dmO2aX;uJGF{e2G7 NGnn[WszPTBxNUCwcm0> NW\vNHlGPDhiaB?= NVPNO5IxyqCSQmO= NV3pOHhR\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NXLWRmo4OjR2MkO2NVM>
HCT-116 MXTGeY5kfGmxbjDBd5NigQ>? MnfXNlUxNzVyMH7N NX\UR4c3PDhiaB?= Mo\HxsBRSlN? MmPN[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? NVLJU4E4OjR2MkO2NVM>
U937-A/E-9/14/18  MUjBdI9xfG:|aYOgRZN{[Xl? M4S2cFAvODFxMD6xM|EwOTBizszN MofOOFghcA>? NHLaWHBqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NY\lVY5qOjR|MEC0OVY>
HT29 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XOO|czKGh? NH61OI9KSzVyPUG0NFDDuTF5OTFOwG0> MXKyOFE4OjB4MR?=
SW48 MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG0O|IhcA>? NHTTS5BKSzVyPUG1MlLDuTZwMjFOwG0> NVnHVnZ3OjRzN{KwOlE>
HCT116 M4DRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEGwe5Y4OiCq MojpTWM2OD1zLkhCtVAvPCEQvF2= M2[2VlI1OTd{ME[x
HepG2 NFHZW4VHfW6ldHnvckBCe3OjeR?= NXXXdY9JOC53L{Gg{txO NHixVFEzPCCq NYS2d|FHTE2VTx?= MnX0eZAuemWpdXzheIVlKHSqZTDy[YxifGm4ZTDPR3RPOiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? MYWyOFE1Pjh5NB?=
LS174T Mn;1SpVv[3Srb36gRZN{[Xl? NIn6dHUxNjVxMTFOwG0> M3XpXlI1KGh? NH;2c4VFVVOR NH3zbFRt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> NFnXcW4zPDF2Nki3OC=>
HepG2 M3X4bWFxd3C2b4Ppd{BCe3OjeR?= M3m4SVEwOTBxMUCwJO69VQ>? M2D3clch\A>? NGrpb|NFVVOR MnuzbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MknVNlQyPDZ6N{S=
LS174T M3e5XmFxd3C2b4Ppd{BCe3OjeR?= MoDyNU8yOC9zMECg{txO MkjDO{Bl MYXEUXNQ NFS5PGVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mn7uNlQyPDZ6N{S=
QBC-939 MXXBdI9xfG:|aYOgRZN{[Xl? NVG5fmQ6OS9zMD:xNFAh|ryP NF;IW2Q4KGR? NFWwSHRFVVOR NHf0XYFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWiyOFE1Pjh5NB?=
U251 NWTHfW9vSXCxcITvd4l{KEG|c3H5 NWm0UYVvOS9zMD:xNFAh|ryP MXy3JIQ> NX;IZ2lHTE2VTx?= MWjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4Lx[FI1OTR4OEe0
HL-60 Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfLbpF1OSEQvF2= MXq0PEBp M{K2c4lv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w MkT2NlQxODB|MkS=
MDA‑MB‑453 M1PW[mZ2dmO2aX;uJGF{e2G7 Mk\PNE4zNzFizszN NEnRVVI4OiCq NEfReZJk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MV[yN|g1PDJ{OB?=
HCC1569 M4DucWZ2dmO2aX;uJGF{e2G7 NIC2fJUxNjJxMTFOwG0> NUjrVnNZPzJiaB?= MoLsZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NX;5fo9MOjN6NESyNlg>
BT‑474 NWTKPYFjTnWwY4Tpc44hSXO|YYm= M170fFAvOi9zIN88US=> MXW3NkBp MlTqZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg MmPXNlM5PDR{Mki=
AGS NYPRc|ZuSXCxcITvd4l{KEG|c3H5 M3nXU|UwOTBxMkCvOVAh|ryP NIjsdlc1QMLiaNMg MX3EUXNQ MnO5bY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> MlLFNlM2QDJ5OES=
A549 NXTVWZlOSXCxcITvd4l{KEG|c3H5 NYPyUo92PS9zMD:yNE82OCEQvF2= NXTNOZJZPDkEoHlCpC=> NFrybZlFVVOR M2\VRYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh NGK1dYQzOzV6Mke4OC=>
AGS  M4TDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVi1M|ExNzJyL{WwJO69VQ>? NILCUlg1QMLiaNMg NVnIXJU3TE2VTx?= Mm\PbY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg NXzCR3F5OjN3OEK3PFQ>
Kasumi-1 M33vdmFxd3C2b4Ppd{BCe3OjeR?= M4nDU|AvPSEQvF2= NIDOSZg1QMLiaNMg MkfW[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NEno[IszOzR7M{O0PC=>
OCI-AML3 M2TXOGFxd3C2b4Ppd{BCe3OjeR?= M{nydFIvPSEQvF2= NFTofZM1QMLiaNMg NXHuU|NO\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> NHnJeG0zOzR7M{O0PC=>
MV4-11 NFnNSW1CeG:ydH;zbZMhSXO|YYm= M2TsOlIvPSEQvF2= M13DTFQ5yqCqwrC= Mo\Q[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= MV[yN|Q6OzN2OB?=
NK  M4DXdWN6fG:2b4jpeJkhSXO|YYm= MWqwMlAzNTJyIN88US=> M4j5RVUh\A>? MmDz[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26|ZTDjeZJ3\Q>? NWfuZYlkOjN|MkiwPFg>
NK  NXjqPYhZSXCxcITvd4l{KEG|c3H5 NX;DbWVnOC5yMj2yNEDPxE1? NX\IWW1JPSCm M4XPZYRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>? MnnWNlM{OjhyOEi=
NK  M{PGVGZ2dmO2aX;uJGF{e2G7 NH\IOHcxNjBzLUKwJO69VQ>? NXzifIV5PSCm MnPKZ4F2e2W|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=> NIWyd|kzOzN{OEC4PC=>
MOLT4/DNR MXXGeY5kfGmxbjDBd5NigQ>? NFXFb2E2KM7:TR?= Moq2OEBl NWX5XJNYemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? M2fiZlI{ODZyNUew
Jurkat/DOX MWnGeY5kfGmxbjDBd5NigQ>? NFLXeFA2KM7:TR?= M3LWeVQh\A>? NGHB[WRz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? NYrOfItsOjNyNkC1O|A>
MOLT4/DNR NE\CZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HYWVUh|ryP M3fke|Qh\A>? NUP2eW0yemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> NYjPXpBsOjNyNkC1O|A>
Jurkat/DOX NV\WOmJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;jfIFkPSEQvF2= NH3JPYg1KGR? MWDy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 NICyZYUzOzB4MEW3NC=>
ccRCC  M2HqR2Fxd3C2b4Ppd{BCe3OjeR?= MV:wMlAyNTFyzszN NWLhVWdUPzJiaB?= MoTmSG1UVw>? NV3y[G1tcGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= NF3URZIzOjh{NkS2Oy=>
TNBC  MWLBdI9xfG:|aYOgRZN{[Xl? NVfRc5dNOC5yMT2xNO69VQ>? M3HWNFczKGh? MV3EUXNQ M37a[4hieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? MYCyNlgzPjR4Nx?=
A498 MmOwRZBweHSxc3nzJGF{e2G7 MVWwMlAyNTFyzszN MWO3NkBp NGWyfpZFVVOR M4PVPIlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MmPFNlI5OjZ2Nke=
KIJ265T M{jhU2Fxd3C2b4Ppd{BCe3OjeR?= MoPLNE4xOS1zMN88US=> NF;lT2s4OiCq M1vEOGROW09? MVzpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MorONlI5OjZ2Nke=
MDA-231 NHzuNZFCeG:ydH;zbZMhSXO|YYm= MojINE4xOS1zMN88US=> NWXVTmREPzJiaB?= NH\pZpRFVVOR NEPkR45qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NITTZogzOjh{NkS2Oy=>
BT-20 MVHBdI9xfG:|aYOgRZN{[Xl? MXuwMlAyNTFyzszN MoWxO|IhcA>? MXXEUXNQ MYDpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NXPOb3k2OjJ6Mk[0Olc>
U937 NEXIVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnySlQ2NTJyIN88US=> MUmyOE81QC95MjDo MorFbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NEK1bnEzOjd4N{CyNS=>
HL60 M2PEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfuSXdIPS1{MDFOwG0> NFO5O4wzPC92OD:3NkBp NWDuOGtbcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MoHtNlI4PjdyMkG=
U937 M2DhS2Fxd3C2b4Ppd{BCe3OjeR?= M1;YXFE2KM7:TR?= NUXBT2c4OjRxNEivO|IhcA>? MkPUbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M1\JelIzPzZ5MEKx
HL60 NEnac|VCeG:ydH;zbZMhSXO|YYm= MVmxOUDPxE1? MX:yOE81QC95MjDo M37Zeolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MkGyNlI4PjdyMkG=
LS411N  MnzyRZBweHSxc3nzJGF{e2G7 M2X4UFAvPSEQvF2= M3zlb|czKGh? M{\lZolv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= MVKyNlQ3OTZ7NR?=
MDA-MB-231 NI\DUYFCeG:ydH;zbZMhSXO|YYm= MlzTNVAh|ryP M3i4OVQ5KGh? MojIdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MkjhNlE5QDd4OUe=
MCF-7  MoDDRZBweHSxc3nzJGF{e2G7 M{HYO|ExKM7:TR?= M{Hn[|Q5KGh? MlTEdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NEHj[IIzOTh6N{[5Oy=>
A375 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7VNE42KM7:TR?= MknoNU82NzhiZB?= MnHWbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NYS3S2I2OjF5OU[2NlI>
SKMEL1 M4TZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHqZVR5OC53IN88US=> NYnhdIU6OS93L{ig[C=> M3\UdYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MkTrNlE4QTZ4MkK=
SKMEL3 NHL2TnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuwMlUh|ryP MVKxM|UwQCCm NIi3UJlqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M3Owe|IyPzl4NkKy
SKMEL28 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITZTnkxNjVizszN Mn\KNU82NzhiZB?= M4nRT4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| Ml34NlE4QTZ4MkK=
MeWo M1Xa[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuwMlUh|ryP MV6xM|UwQCCm MnHBbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MlzGNlE4QTZ4MkK=
B16 M17xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6wMlUh|ryP M1TldFEwPS96IHS= MVHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? M{fzbVIyPzl4NkKy
Ly 1 NXHIRolnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;NNlQhcA>? MWDJR|UxRTdwMzFOwG0> M3j6U|IyPzd{MES5
Ly 7 M4LpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fLT|I1KGh? Mlj2TWM2OD1zMD63JO69VQ>? MXyyNVc4OjB2OR?=
Su-DHL6 NVLzVYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDZW4wzPCCq NYT4eY9ZUUN3MP-8olIxKM7:TR?= NUe3b|BsOjF5N{KwOFk>
Ly 10 M{DYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\uNlQhcA>? NXfQXIR2UUN3MP-8olIxKM7:TR?= NXjmdYdKOjF5N{KwOFk>
RIVA NVux[5h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DGbVI1KGh? M3PMcmlEPTExvK6yNEDPxE1? NWDXco0yOjF5N{KwOFk>
Su-DHL2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfIe|EzPCCq NXrMVWNHUUN3MP-8olIxKM7:TR?= NV73OpZYOjF5N{KwOFk>
Ly 1 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHKSnNLPDhiaB?= NV;FXmxuUUN3ME2wMlM1KM7:TR?= NYfiNY51OjF5N{KwOFk>
Ly 7 NWHlbY5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HPOVQ5KGh? MXvJR|UxRTBwMEK1JO69VQ>? NXjGVWhHOjF5N{KwOFk>
Su-DHL6 NWrRRpRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVS0PEBp Mn3nTWM2OO,:nkKwJO69VQ>? MVWyNVc4OjB2OR?=
Ly 10 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[0PEBp MoLmTWM2OD1zLkig{txO MkPlNlE4PzJyNEm=
RIVA Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL5ZnQ1QCCq M3XoRmlEPTExvK6yNEDPxE1? MoXaNlE4PzJyNEm=
Su-DHL2 NWHhdGttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYq0PEBp NEW3Z5lKSzVyPUG3MlQh|ryP MYSyNVc4OjB2OR?=
Ly 1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq5O|IhcA>? NYrFR3dNUUN3ME2wMlAyKM7:TR?= M1fVeFIyPzd{MES5
Ly 7 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrhZ4Y4OiCq NWHXUoNDUUN3ME2wMlAyQCEQvF2= M2[2VlIyPzd{MES5
Su-DHL6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{joU|czKGh? NV61XppFUUN3ME2xMlYh|ryP NWT2WXhiOjF5N{KwOFk>
Ly 10 MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnCVFhwPzJiaB?= NGLNdIdKSzVyPUGuNkDPxE1? MWWyNVc4OjB2OR?=
RIVA NV3aeohYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojUO|IhcA>? MWnJR|Ux97zgMkCg{txO M3vxeFIyPzd{MES5
Su-DHL2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDEdXd4PzJiaB?= MWPJR|UxRTFzLkKg{txO NHmzfXUzOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03017131 Recruiting Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma Roswell Park Cancer Institute|National Cancer Institute (NCI) December 8 2017 Phase 1
NCT03021395 Recruiting AML Institute of Hematology & Blood Diseases Hospital February 8 2017 Phase 1|Phase 2
NCT03226418 Recruiting Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia University of Nebraska|National Cancer Institute (NCI) July 7 2017 Phase 2
NCT02839694 Withdrawn Neoplasm Metastasis|Sarcoma|Neoplasms Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2016 Phase 1
NCT02203773 Active not recruiting Acute Myelogenous Leukemia|Myelogenous Leukemia|Treatment Naive AML AbbVie|Genentech Inc. July 7 2015 Phase 1|Phase 2
NCT03066648 Recruiting Leukemia|Leukemia Myeloid|Leukemia Myeloid Acute|Myelodysplastic Syndromes|Preleukemia|Bone Marrow Diseases|Hematologic Diseases Novartis Pharmaceuticals|Novartis July 6 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID